These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6998796)

  • 1. Local therapy of atrophic vaginal conditions with oestriol suppositories.
    Michalas S; Papandrikos A; Koutselini E; Tzingounis V
    J Int Med Res; 1980; 8(5):358-60. PubMed ID: 6998796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The treatment of atrophic vaginal conditions with Ortho-Gynest: a pilot study.
    Karoussos KE; Studer S; Wyss HJ
    J Int Med Res; 1979; 7(6):569-72. PubMed ID: 520660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovestin vaginal cream and suppositories for the treatment of menopausal vaginal atrophy.
    Trevoux R; van der Velden WH; Popović D
    Reproduccion; 1982; 6(2):101-6. PubMed ID: 7141096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, cytological and biological study of the intra-vaginal administration of oestriol (Ortho-Gynest) in post-menopausal patients.
    Wesel S; Etienne J; Lestienne MC
    Maturitas; 1981 Dec; 3(3-4):271-7. PubMed ID: 7334936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Practical observations on the use of the Ortho-Gynest vaginal globules from the firm of Cillag--Switzerland].
    Milchev N; Grozdanov G; Krumov G
    Akush Ginekol (Sofiia); 1993; 32(2):46. PubMed ID: 8010406
    [No Abstract]   [Full Text] [Related]  

  • 6. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol.
    Griesser H; Skonietzki S; Fischer T; Fielder K; Suesskind M
    Maturitas; 2012 Apr; 71(4):360-8. PubMed ID: 22285095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy.
    Dugal R; Hesla K; Sørdal T; Aase KH; Lilleeidet O; Wickstrøm E
    Acta Obstet Gynecol Scand; 2000 Apr; 79(4):293-7. PubMed ID: 10746845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experience with an injectionable estriol Depot preparation. (Gynaesan pro injectione)].
    Lauritzen C
    Munch Med Wochenschr; 1968 May; 110(19):1203-6. PubMed ID: 5695211
    [No Abstract]   [Full Text] [Related]  

  • 9. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel.
    Caruso S; Cianci S; Amore FF; Ventura B; Bambili E; Spadola S; Cianci A
    Menopause; 2016 Jan; 23(1):47-54. PubMed ID: 26079974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endometrial morphology after 12 months of vaginal oestriol therapy in post-menopausal women.
    Gerbaldo D; Ferraiolo A; Croce S; Truini M; Capitanio GL
    Maturitas; 1991 Oct; 13(4):269-74. PubMed ID: 1775080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of postmenopausal vaginal atrophy with Ovestin vaginal cream or suppositories: clinical, endocrinological and safety aspects.
    Kicovic PM; Cortes-Prieto J; Milojević S; Haspels AA; Aljinovic A
    Maturitas; 1980 Dec; 2(4):275-82. PubMed ID: 6785553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
    Palacios S; Castelo-Branco C; Cancelo MJ; Vázquez F
    Maturitas; 2005 Feb; 50(2):98-104. PubMed ID: 15653006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intravaginal treatment of colpitis maculosa with an oestriol-containing vaginal cream (author's transl)].
    Schröck A; Kofler K; Baumgarten K; Endl J; Schmidt J; Tatschl S
    Wien Klin Wochenschr; 1981 Dec; 93(23):713-6. PubMed ID: 7342467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review.
    Mueck AO; Ruan X; Prasauskas V; Grob P; Ortmann O
    Climacteric; 2018 Apr; 21(2):140-147. PubMed ID: 29381086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study.
    Cano A; Estévez J; Usandizaga R; Gallo JL; Guinot M; Delgado JL; Castellanos E; Moral E; Nieto C; del Prado JM; Ferrer J
    Menopause; 2012 Oct; 19(10):1130-9. PubMed ID: 22914208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy.
    Mariani L; Gadducci A; Vizza E; Tomao S; Vici P
    Gynecol Endocrinol; 2013 Jan; 29(1):25-9. PubMed ID: 22994445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transvaginal estriol administration in postmenopausal women: a double blind comparative study of two different doses.
    Bottiglione F; Volpe A; Esposito G; Aloysio DD
    Maturitas; 1995 Nov; 22(3):227-32. PubMed ID: 8746880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints.
    Foidart JM; Vervliet J; Buytaert P
    Maturitas; 1991 Jun; 13(2):99-107. PubMed ID: 1921739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical evaluation of lactovagil].
    Moreno Vázquez LF; Madrid Rivera H
    Prensa Med Mex; 1976; 41(11-12):428-31. PubMed ID: 829157
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women.
    Dessole S; Rubattu G; Ambrosini G; Gallo O; Capobianco G; Cherchi PL; Marci R; Cosmi E
    Menopause; 2004; 11(1):49-56. PubMed ID: 14716182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.